Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Tocilizumab for the treatment of juvenile idiopathic arthritis

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Roche Products (tocilizumab) Patient/carer groups • Action for Children • Action for Sick Children • Action on Pain • Afiya Trust • Arthritic Association • Arthritis and Musculoskeletal Alliance (ARMA) • Arthritis Care • Back Care • Black Health Agency • Child Growth Foundation • Children's Chronic Arthritis Association • Children's Society • Chinese National Healthy Living Centre • Equalities National Council • Leonard Cheshire Disability • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Royal Association for Disability and Rehabilitation (RADAR) • South Asian Health Foundation • Specialised Healthcare Alliance • Wellchild Professional groups • Bone Research Society • British Health Professionals in	General • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Association of Primary Care • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium Possible comparator manufacturer(s) • Actavis (azathioprine, sulfasalazine, penicillamine) • Alliance Pharmaceuticals (penicillamine) • Almus Pharmaceuticals (sulfasalazine) • Arrow Generics (azathioprine) • Astellas (auranofin) • AstraZeneca (chloroquine) • Focus Pharmaceuticals (azathioprine) • GlaxoSMithKline (azathioprine) • IVAX Pharmaceuticals (azathioprine, sulfasalazine) • Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) • Mayne Pharma (methotrexate) • Medac UK (methotrexate) • Mylan (azathioprine, sulfasalazine, penicillamine)

Consultees	**Commentators (no right to submit or appeal)**
Rheumatology • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Pain Society • British Society for Paediatric and Adolescent Rheumatology • British Society for Rheumatology • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • College of Occupational Therapists • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine - Forum on Intellectual Disabilities • United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • Isle of Wight PCT • Leicester City West PCT • Welsh Assembly Government	• Novartis (ciclosporin) • Pfizer (sulfasalazine) • Sandoz (azathioprine) • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate) • Teva UK (azathioprine, sulfasalazine, penicillamine) • Waymade Healthcare (sulfasalazine) • Wockhardt UK (methotrexate) <u>Relevant research groups</u> • Arthritis Research UK • MRC Clinical Trials Unit • National Institute for Health Research <u>Evidence Review Group</u> • National Coordinating Centre for Health Technology Assessment • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York <u>Associated Guideline Groups</u> • National Clinical Guideline Centre (NCGC) • National Collaborating Centre for Women's and Children's Health (NCCWCH)

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.